Clinical Outcomes of Gamma Knife Radiosurgery for Metastatic Brain Tumors from Gynecologic Cancer : Prognostic Factors in Local Treatment Failure and Survival.
10.3340/jkns.2016.59.4.392
- Author:
Hong Kyung SHIN
1
;
Jeong Hoon KIM
;
Do Heui LEE
;
Young Hyun CHO
;
Do Hoon KWON
;
Sung Woo ROH
Author Information
1. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykwon@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Gynecologic cancer;
Brain metastases;
Gamma Knife Radiosurgery;
Prognostic factor;
Survival
- MeSH:
Brain Neoplasms*;
Brain*;
Classification;
Ethics Committees, Research;
Female;
Follow-Up Studies;
Humans;
Karnofsky Performance Status;
Multivariate Analysis;
Neoplasm Metastasis;
Radiosurgery*;
Retrospective Studies;
Treatment Failure*;
Tumor Burden
- From:Journal of Korean Neurosurgical Society
2016;59(4):392-399
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Brain metastases in gynecologic cancer (ovarian, endometrial, and cervical cancer) patients are rare, and the efficacy of Gamma Knife Radiosurgery (GKRS) to treat these had not been evaluated. We assessed the efficacy of GKRS and prognostic factors for tumor control and survival in brain metastasis from gynecologic cancers. METHODS: This retrospective study was approved by the institutional review board. From May 1995 to October 2012, 26 women (mean age 51.3 years, range 27-70 years) with metastatic brain tumors from gynecologic cancer were treated with GKRS. We reviewed their outcomes, radiological responses, and clinical status. RESULTS: In total 24 patients (59 lesions) were available for follow-up imaging. The median follow-up time was 9 months. The mean treated tumor volume at the time of GKRS was 8185 mm³ (range 10-19500 mm³), and the median dose delivered to the tumor margin was 25 Gy (range, 10-30 Gy). A local tumor control rate was 89.8% (53 of 59 tumors). The median overall survival was 9.5 months after GKRS (range, 1-102 months). Age-associated multivariate analysis indicated that the Karnofsky performance status (KPS), the recursive partitioning analysis (RPA) classification, and the number of treated lesions were significant prognostic factors for overall survival (HR=0.162, p=0.008, HR=0.107, p=0.038, and HR=2.897, p=0.045, respectively). CONCLUSION: GKRS is safe and effective for the management of brain metastasis from gynecologic cancers. The clinical status of the patient is important in determining the overall survival time.
